(PRINCETON, N.J.)Pharmasset Inc. said Tuesday its hepatitis C treatment candidate met safety goals in part of an early-stage study. The drug candidate, called R7128, was administered to patients ov...READ MORE

(NEW YORK)Clinical-stage pharmaceutical company Pharmasset Inc. said Tuesday it has sold 1.45 million shares of stock to institutional investors, raising about $25.9 million.READ MORE

(PRINCETON, N.J.)Clinical-stage pharmaceutical company Pharmasset Inc. said Monday that it has selected PSI-7851, a preclinical drug for treatment of hepatitis C virus, as its lead candidate for tr...READ MORE

(NEW YORK)Shares of clinical-stage pharmaceutical company Pharmasset Inc. rose Friday after analysts expressed optimism about the company's hepatitis Cdrug candidate in partnership with ...READ MORE

Among the stock activity stories for Friday, May 16, from AP Financial News: NEW YORK (AP) _ Shares of Melco PBL Entertainment Inc. fell Friday as investors largely discounted the ...READ MORE

(PRINCETON, N.J.)Pharmasset Inc., a clinical-stage pharmaceutical company, said Friday its hepatitis C drug candidate R7128 met safety goals in an early-stage study. The study results were presente...READ MORE

(NEW YORK) Shares of Pharmasset Inc. rose Wednesday, as a UBS analyst upgraded the antiviral drugmaker, citing its low share price and strong hepatitis B and C pipeline. Analyst Annabel Sam...READ MORE